You are here

  • Home
  • Archive
  • Volume 9, Issue 4
  • Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Article Text

Article menu
Download PDFPDF
Therapeutics
Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

http://dx.doi.org/10.1136/ebmh.9.4.100

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231–42.OpenUrlCrossRefPubMedWeb of Science

    Q Is sustained-release bupropion, sertraline, or extended-release venlafaxine effective for people with major depressive disorder in whom citalopram is not effective?

    METHODS

    Embedded ImageDesign:

    Randomised controlled trial.

    Embedded ImageAllocation:

    Unconcealed.

    Embedded ImageBlinding:

    Unblinded.

    Embedded ImageFollow up period:

    14 weeks.

    Embedded ImageSetting:

    Eighteen primary and 23 psychiatric public and private practices, USA. Enrolled: July 2001 to August 2004.

    Embedded ImagePatients:

    727 people with non-psychotic major depressive disorder who were intolerant of citalopram or in whom citalopram did not produce remission (failure to remit: Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C-16) score >5). Inclusion criteria were described as being broad with limited exclusions. Detailed exclusion criteria included: concomitant antidepressants outside of the protocol, mood stabilisers, antipsychotics, anticonvulsants, and stimulants.

    Embedded ImageIntervention:

    Sustained-release bupropion (150 mg/day for 1 week, …

    View Full Text

    Footnotes

    • For correspondence: Dr A John Rush, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9086, USA; john.rush{at}utsouthwestern.edu

    • Sources of funding: National Institute of Mental Health and National Institutes of Health, USA.